| 0.3365 -0.013 (-3.83%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.43 | 1-year : | 0.48 |
| Resists | First : | 0.37 | Second : | 0.41 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.29 | Second : | 0.24 |
| MAs | MA(5) : | 0.34  |
MA(20) : | 0.34 |
| MA(100) : | 0.55 |
MA(250) : | 0.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.7 |
D(3) : | 38.4 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 1.69 | Low : | 0.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TVGN ] has closed above bottom band by 40.3%. Bollinger Bands are 29.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.36 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.33 - 0.34 | 0.34 - 0.34 |
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Mon, 12 Jan 2026
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 - The Globe and Mail
Thu, 08 Jan 2026
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - simplywall.st
Tue, 09 Dec 2025
Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Mon, 08 Dec 2025
Tevogen (Nasdaq: TVGN) on NJBIZ Power List with $18–22B outlook, NJ expansion - Stock Titan
Mon, 08 Dec 2025
Tevogen Bio Holdings Inc. Recognized in 2025 New Jersey Power List for Innovation and Economic Impact - Quiver Quantitative
Fri, 14 Nov 2025
Tevogen Bio Holdings Inc. SEC 10-Q Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 199 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 78.3 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 1,980 (K) |
| Shares Short P.Month | 2,230 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -439.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -1.87 |
| PEG Ratio | 0 |
| Price to Book value | -4.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|